The search for next-generation KRAS drugs that can do what Amgen and Bristol Myers Squibb’s medicines can’t has led to Medicxi’s first-ever investment in China.
The European VC firm is pouring $40 million into Shanghai-based D3 Bio, whose KRAS G12C inhibitor is currently in Phase 2…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
